Note: Use EDIT then FIND in your Internet explorer tool bar to search this table

PROTOCOL

AA-DESCRIPTION-AA

NUM

CALG-B (LARSON) INDUCTION

ALL (Acute Lymphoblastic Leukemia)

REFER: Larson RA, et al: PROC ASCO 1992; 11:263.

CYCLOPHOSPHAMIDE 1200 mg/m2 IV D1

DAUNORUBICIN 45 mg/m2 per day IV D1-3

VINCRISTINE 1.4 mg/m2 IV D1,8,15,22

PREDNISONE 60 mg/m2 per day PO...D1-21

L-ASPARAGINASE 6000 iu/m2 IV D5,8,11,15,18,22

226

MidAC5+3

AML (Acute Myeloid Leukemia) - MRC Protocol

Trial: AML 15

MITOXANTRONE 10MG/M2 d1-5

CYTATABINE 2 G/M2 d1-3

137

ADE

10/8+3+5

AML - MRC protocol

Trials: AML 15 AND AML HR

CYTARABINE 200MG/M2 10(8)DAY

DAUNORUBICIN 50MG/M2 D1,3,5

ETOPOSIDE 100MG/M2 5 DAYS

102

DA 3+8/10

AML - MRC Protocol

Trial: MRC AML 15

DAUNORUBICIN 50MG/M2 D 1,3,5

CYTARABINE 200MG/M2 D 1-8/10

135

A+D(7+3)

AML - variant of DAT

REFER: Dillman RO, et al: BLOOD 1991; 78:2520-2526.

DAUNORUBICIN 45 MG/M2/DAY d1-3(2)

CYTARABINE 100 MG/M2/DAY d1-7(5)

227

ADE(7+3+7)

INDUCTION

AML

REF: Bishop J, et al: BLOOD 1990; 1/1 75(1):27-32.

CYTARABINE 100 mg/m2 per day CIV D1-7

DAUNORUBICIN 50 mg/m2 per day IV D1-3

ETOPOSIDE 75 mg/m2 D1-7

228

MC INDUCTION

AML

REF: Arlin Z, et al: LEUKEMIA 1990; 4:177-183.

MITOXANTRONE 12 mg/m2 IV D1-3

CYTARABINE 100 mg/m2 CIV D1-7

232

FLAG-Ida

AML - MRC Protocol

Trial: AML 15

IDARUBICIN 10 MG/M2/DAY d4-6

CYTARABINE 2 G/M2/DAY d2-6

FLUDARABINE 30MG/M2/DAY d2-6

G-CSF (LENOGRASTIM) 263 UG SC DAY 1-7

130

IDA-AR2

CONSOL

AML

REF: Vogler WR, et al: J CLIN ONCOL 1992; 10:1103-1111.

THIOGUANINE 100 mg/m2 PO BD D1-5

CYTARABINE 100 mg/m2 IV BD D1-5

IDARUBICIN 15 mg/m2 IV D1

231

IDA-AR1 INDUCTION

AML

REF: Vogler WR, et al: J CLIN ONCOL 1992; 10:1103-1111.

IDARUBICIN 12 mg/m2 IV D1-3

CYTARABINE 100 mg/m2 CIV D1-7

230

HiDAC

AML

REF: Bloomfield CD, Herzig GP, eds.: HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA 1993; 7:47-79.

CYTARABINE 1.5-3 g/m2 IV BD D1-4(6)

229

High-dose Ara-C 

AML - MRC Protocol

Trial: AML 15

CYTARAABINE 1.5 OR 3.0 G/M2 BD d1, 3, 5

139

Gemtuzumab

MYLOTARG

Gemtuzumab (MYLOTARG) 9 MG/M2 DAY 1

131

DAT

AML - MRC Protocol; & variants

Trial: AML 9?

DAUNORUBICIN 50 MG/M2/DAY d1(3)(5)

CYTARABINE 200 MG/M2/DAY d1-(5)(7)(10)

THIOGUANINE 200MG/M2/DAY d1-(5)(7)(10)

113

 

D50A400

AML - MRC Protocol; variant of DAT

Trial: AML 14

DAUNORUBICIN 50 MG/M2/DAY d1-3

CYTARABINE 400 MG/M2/DAY d1-8(10)

THIOGUANINE 200MG/M2/DAY d1-8(10)

128

D35A200

AML - MRC Protocol; variant of DAT

Trial: AML 14

DAUNORUBICIN 35 MG/M2/DAY d1-3

CYTARABINE 200 MG/M2/DAY d1-8(10)

THIOGUANINE 200MG/M2/DAY d1-8(10)

129

MAC

AML

Mitozantrone 12mg/m2 d1,3,(5)

Cytarabine 200mg/m2/day d1-5

117

ICE 2+3

AML - MRC Protocol

Trial AML 14

IDARUBICIN 10MG/M2 d1,2

CYTARABINE 200 MG/M2 d1-3

ETOPOSIDE 100MG/M2 d1-3

134

MACE

AML - MRC Protocol

Trials: AML 15

AMSACRINE 100MG/M2 5 d1-5

CYTARABINE 200MG/M2 5 d1-5

ETOPOSIDE 100MG/M2 5 d1-5

136

FLA(G)

AML - MRC Protocol

Trials: AML 12 & HR

FLUDARABINE 30MG/M2 d1-5

CYTARABINE 2G/M2 d1-5

+/- G-CSF 5ug/kg/day +/- ATRA 45 mg/m2/day

140

D50A200

AML - MRC Protocol; variant of DAT

Trial: AML 14

DAUNORUBICIN 50 MG/M2/DAY d1-3

CYTARABINE 200 MG/M2/DAY d1-8(10)

THIOGUANINE 200MG/M2/DAY d1-8(10)

127

D35PA400

AML - MRC Protocol; variant of DAT

Trial: AML 14

DAUNORUBICIN 35 MG/M2/DAY d1-3

PSC833 32 mg/kg 72 hr inf d1-3

CYTARABINE 400 MG/M2/DAY d1-8(10)

THIOGUANINE 200MG/M2/DAY d1-8(10)

132

ICE 3+5

AML - MRC Protocol

Trial AML 12

IDARUBICIN 10MG/M2 d1-3

CYTARABINE 200 MG/M2 d1-5

ETOPOSIDE 100MG/M2 d1-5

133

FU-MMC-XRT

Anus

REF: Tanum G, et al: CANCER 1991; 67:2462-2466.

FLUOROURACIL 1000 mg/m2 CIV D1-4

MITOMYCIN C 10 - 15 mg/m2 IV D1

Concomitant XRT q 28d

221

SMF

Pancreatic Ca

REF: 

Streptozotocin 1000mg/m2 Week 1,2,5,6

Fluorouricil 600 mg/m2 IV  week 1,2,5,6

Mitomycin C  10 mg/m2 IB D1 Q56 d

223

MVAC

BLADDER CA - TRANSITIONAL CELL

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 224-225.

METHOTREXATE 30 mg/m2 IV D1,15,22

VINBLASTINE 3 mg/m2 IV D2,15,22

DOXORUBICIN 30 mg/m2 IV D2

CISPLATIN 70 mg/m2 IV D2 q 28d

225

EP

Cervix Cancer - non small cell

ETOPOSIDE 60 mg/m2 IV D1-3

ETOPOSIDE 50 mg/m2 PO d4-10

CISPLATIN 30 mg/m2 per day IV D1-3 q28d

 270

MACE

Gestational Trophoblastic Carcinoma - High Risk

ETOPOSIDE 100 mg po D1-10

Actinomycin D 0. 50 mg/m2 PO d8,9

Methotrexate 400 mg/m2 d8

CISPLATIN 30 mg/m2 per day IV D1-3 q14d

 275

MTX+DACT

Gestational Trophoblastic Carcinoma - Low Risk

Dactinomycin 0.60 mg/m2 PO d1,2

Methotrexate 400 mg/m2 d8 V D1-3 q14d

 276

EP

Testicular Cancer

ETOPOSIDE 100 mg/m2 per day IVD1-5

(reduce by 20% if prior XRT)

CISPLATIN 20 mg/m2 per day IV D1-5 q21d

 243

FP

GU Tract Ca SQUAMOUS carcinoma of Penis

GI Tract Ca Oesophageal Cancer

Fluorouricil 1000 mg/m2 per day IV inf D1-4

CISPLATIN 25 mg/m2 per day IV D1-3 q28d

 244

FUC

GI Tract Ca Oesophageal, Stomach, Gall bladder Cancer, cholangiocarcinoma

Fluorouricil 1000 mg/m2 per 24h IV inf D1,2

CISPLATIN 25 mg/m2 od IV D1 q7

 255

Mitomycin C

Prostate Cancer - 

Adenocarcinoma

Mitomycin C 12 mg/m2 IV  d1 q28

 246

Mitoxantrone + Prednisolone

Prostate Cancer - 

Adenocarcinoma

Mitoxantrone C 12 mg/m2 IV  d1 

Prednisolone 10 mg d1-21   q21

 247
Doxorubicin Thyroid - Medullary Carcinoma

GI Tract - Hepatoma (Metastatic)

Doxorubicin 60 mg/m2 d1 q21

 250

Gemcitabine

Pancreas Adenocarcinoma

Ref: Skeel R Handbook of Cancer Chemotherapy, 5th Ed, Lipincott Williams and Wilkins 1999,  p109

Gemcitabine  1000 mg IV  D1,8,15,22,29,36,43   q 49

 		257

Cisplatin + Gemcitabine

LUNG - mesothelioma

CISPLATIN 75 mg/m2 IV D1

Gemcitabine  1250  IV  D1,8   q 21

 		268

Cisplatin + Gemcitabine

Bladder - Urothelial

CISPLATIN 70 mg/m2 IV D1

Gemcitabine  1000  IV  D1,8,15   q 28

Alternative:

CISPLATIN 70 mg/m2 IV D1

Gemcitabine  1250  IV  D1,8   q 21

 241

Gemcitabine 

Ovarian - Epithelial Cell

Gemcitabine  800  IV  D1,8,15   q 28

 		274

Carboplatin + Gemcitabine

Bladder - Urothelial

CARBOPLATIN  (5 X (GFR + 25)) mg  IV  D1

Gemcitabine  1000  IV  D1,8,15   q 28

Alternative:

Carboplatin (5 x (GFR +25))  mg IV D1

Gemcitabine  1250  IV  D1,8   q 21

 		242

Carboplatin 

Seminoma  - Stage 1 high risk

CARBOPLATIN  (7 X (GFR + 25)) mg  IV  D1  q 28 - two cycles

 248

Topotecan

Ovarian  - Epithelial

Topotecan  1.25  mg/m2  IV  D1-5  q 21 

 273

Carboplatin 

Ovarian  - Epithelial

CARBOPLATIN  (6 X (GFR + 25)) mg  IV  D1  q 28 

 272
Raltitrexed Colorectal Carcinoma

Raltitrexed 3 mg/m2 IV q21

 258

CMV

Bladder

REF: Harker WG, et al: J CLIN ONCOL 1985; 3:1463-1470.

CISPLATIN 100 mg/m2 IV D2

METHOTREXATE 30 mg/m2 IV D1,8

VINBLASTINE 4 mg/m2 IV D1,8 Q 21d

224

BCNU

BRAIN

CARMUSTINE 80 mg/m2 IV D1-3 Q 6-8 wks

REFER: Walker MD, et al: J NEUROSURG 1978; 49:333-343.

212

 

CCNU

BRAIN

LOMUSTINE 130 mg/m2 po D1  Q 6 wks

260

 

 

PCV

BRAIN TUMOURS

REF: Levin VA, et al: INT J RADIAT ONCOL BIOL PHYS 1990; 18:321-324.

LOMUSTINE 110 mg/m2 PO D1

PROCARBAZINE 60 mg/m2 per day PO D8-21

VINCRISTINE 1.4 mg/m2 IV D8, 22 Q6-8 weeks

213

 

CCV

BRAIN TUMOURS

LOMUSTINE 75 mg/m2 PO D1

CISPLATIN 75 mg/m2 per day IV D1

VINCRISTINE 1.4 mg/m2 IV D1,8,15  Q6 weeks

 261

PROC

BRAIN

REFER: 

PROCARBAZINE 100 mg/m2 PO D1-14  Q28D

214

 

Saltz

Colorectal Cancer

REF: Saltz et al. New Eng J. Med. 343 (13) 905-14, 2000

Irenotecan 100 or 125 mg/m2 IV d1,8,15,22 

Folinic Acid 20 mg/m2 IV d1,8,15,22

Fluorouricil 400 or 500 mg/m2 Iv d1,8,15,22   q 42d

185

 

Degramont

Colorectal Cancer

REF: Douillard JY et al. The Lancet 355: 1041-47, 2000

Irenotecan 185 mg/m2 IV d1 

Folinic Acid 200 mg/m2 IV d1

Fluorouricil  400  mg/m2 Iv d1 bolus then 600mg/m2 22 h inf d1 q14  

 269
     

 

Irenotecan

Colorectal Cancer

Irenotecan 350 mg/m2 IV d1 q15   OR

Irenotecan 125 mg/m2 IV d1,8,15,22 q21

256

GO9502

 BCCA Protocol Summary for Treatment of Small Cell Carcinoma of Cervix Using Paclitaxel, Cisplatin, Etoposide and Carboplatin with Radiation (GO 95 02)

CYCLE

A

B

C

D

E

DAY

1

2

21

22

23

24

25

42

56

70

84

98

126

127

128

129

130

1paclitaxel 175 mg/m2 IV

x

 

 

 

 

 

 

 

 

 

 

x

 

 

 

 

 

2cisplatin 60 mg/m2 IV

x

x

x

x

 

 

 

x

x

x

x

 

 

 

 

 

 

3etoposide 75 mg/m2 IV

 

 

x

x

 

 

 

 

 

 

 

 

 

 

 

 

 

etoposide 100 mg PO

 

 

 

 

x

x

x

 

 

 

 

 

x

x

x

x

x

4carboplatin IV

 

 

 

 

 

 

 

 

 

 

 

x

x

 

 

 

 

5 pelvic/para-aortic XRT 4000 cGy in 25#; selectron x2 or lat. pelvis 1000 cGy in 5#

 

 

 

 

 

186

PACLITAXEL

Breast Cancer, Stage IV

Ovarian Cancer - Epithelial

REF: TAXOL(R) (paclitaxel) Bristol-Myers Squibb Co, prescribing info in PHYSICIANS DESK REFERENCE 49th Ed. Montvale, NJ; 1995;682.

Paclitaxel (Taxol) 175 mg/m2 IV over 3hrs d1 q21

145

PACLITAXEL + CARBOPLATIN

Endometrial Cancer

Paclitaxel (Taxol) 175 mg/m2 IV d1 

Carboplatin 6x(GFR+25) mg IV q21

 271

AC

Breast Cancer, Stage I-IV

Cyclophosphamide 600mg/m2 d1

Doxorubicin 60 mg/m2 d1 q21

143

CMFP

Breast Cancer, Stage I-IV

Marschke RF, et al: CANCER 1989; 63:1931-1937.

Cyclophosphamide 100 mg/m2 po d1-14

Methotrexate 30 mg/m2 iv d1,8

Fluorouricil 600 (modified) mg/m2 d1,8

PREDNISONE 40 mg/m2 PO D1-14 q28

181

CAF(IV)

Breast Cancer, Stage I-IV

REF: Smalley RV, et al: A Southeastern Cancer Study Grp Prj: CANCER 1977; 40:625-632.

Cyclophosphamide 500 mg/m2 IV d1

Doxorubicin 50 mg/m2 IV d1 or over 72h inf

Fluorouricil 500 mg/m2 IV d1 q21

178

CEF

Breast Cancer, Stage I-IV - BCCA protocol 

Cyclophosphamide 75 mg/m2 PO  d1-14

Epirubicin 60 mg/m2 IV  d1,8

Fluorouricil 500 mg/m2 IV d1,8  q28

234
Trastuzamab Breast Cancer Trastuzamab (Herceptin)

Trastuzamab 8 mg/kg first cycle

6mg/kg subsequent cycles   q21

 238
Trastuzamab +

Paclitaxel

 Breast Cancer Trastuzamab + Pacletaxel

Trastuzamab 8 mg/kg d1 Paclitaxel 175mg/m2 d2 - 1st cycle

Trastuzamab 6 mg/kg d1  Paclitaxel 175mg/m2 d1 -     cycles 2-6   q21

 239
Trastuzamab +

Vinorelbine

 Breast Cancer Trastuzamab + Vinorelbine

Trastuzamab 4 mg/kg Vinorelbine 25mg/m2 - first week

 Trastuzamab 4 mg/kg Vinorelbine 25mg/m2 - subsequent weeks   q7

 240

FAC

Breast Cancer, Stage I-IV

REF: Hortobagyi GH, et al: CANCER 1989; 63:37-45. 

Cyclophosphamide 500 mg/m2 IV d1

Doxorubicin 50 mg/m2 IV (modified) d1

Fluorouricil 500 mg/m2 IV d1,8 (modified)

 q21/28

144

Docetaxel + Cisplatin 

Lung Cancer - non small cell

Docetaxel (Taxotere) 75 mg/m2 IV d1 

Cisplatin  75 mg/m2 IV d1  q21

 263

Docetaxel 

Lung Cancer - non small cell

Docetaxel (Taxotere) 75 mg/m2 IV d1 q21

 264

Docetaxel 

Breast Cancer

Docetaxel (Taxotere) 100 mg/m2 IV d1 q21

146

Docetaxel(weekly)

Breast Cancer

Docetaxel (Taxotere) 35 mg/m2 IV d1 q8

237

CAD

Breast Cancer, Stage IV

Docetaxel (Taxotere) 75 mg/m2 IV d1

Capecitabine  1000-1250 mg/m2 po bd q21

235

Docetaxel

Prostate Cancer - hormone refractory 

Docetaxel (Taxotere) 75 mg/m2 IV d1 q21

245

Capecitatbine

Breast Cancer

Colorectal Cancer

Capecitabine  1000-1250 mg/m2 po bd d1-14 q21

 236

MF

Breast Cancer, Stage I-IV

Methotrexate 100 mg/m2 IV d1,8

Fluorouricil 600 mg/m2 IV d1,8

Folinic Acid 10 mg/m2 IV/po qid x6 doses d2,9 q28

184

CNF

Breast Cancer

REF: Bennett JM, et al: J CLIN ONCOL 1988; 6:1611-1620.

CYCLOPHOSPHAMIDE 500 mg/m2 IV D1

MITOXANTRONE 10 mg/m2 IV D1

FLUOROURACIL 500 mg/m2 IV D1 q 21d

182

CAF(PO)

Breast Cancer, Stage I-IV

REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991.

CYCLOPHOSPHAMIDE100 mg/m2 PO D1-14

DOXORUBICIN 30 mg/m2 IV

FLUOROURACIL 500 mg/m2 IV D1,8 q28

179

CMF(PO)

Classical

Breast Cancer, Stage I-IV

REF: Bonadonna G, et al: NEJM 1976; 294:405-410.

Cyclophosphamide 100 mg/m2 po d1-14

Methotrexate 40 mg/m2 iv d1,8

Fluorouricil 600 mg/m2 d1,8 q28

141

CMF(PO)E

Breast Cancer, Stage I-IV

REF: Bonadonna G, et al: NEJM 1976; 294:405-410.

Cyclophosphamide 100 mg/m2 po d1-14

Methotrexate 30 mg/m2 iv d1,8

Fluorouricil 600 (modified) mg/m2 d1,8 q28

180

CMF(IV)

Breast Cancer, Stage I-IV

REF: Weiss RB, et al: AM J MED 1987; 83:455-463.

Cyclophosphamide 600 mg/m2 IV d1

Methotrexate 40 mg/m2 IV d1

Fluorouricil 600 mg/m2 IV d1 q21

142

FAC

(BOLUS)

Breast Cancer, Stage I-IV

REF: Blumenschein G, et al: PROC ASCO 1974; 15:193. 

Cyclophosphamide 500 mg/m2 IV d1

Doxorubicin 50 mg/m2 IVB d1

Fluorouricil 500 mg/m2 IV d1,8 q21

183

VINORELBINE

(weekly)

Breast Cancer

Vinorelbine  30mg/m2 IV weekly

148

VINORELBINE

Breast Cancer

Lung Cancer: Non Small Cell - palliative

Vinorelbine  30mg/m2 IV d1,8 q21

147

CDDP

Cervical Cancer

REF: Skeel RT: Handbook of Cancer Chemotherapy, 5th Ed. Lippincott Williams and Wilkins. 1999; 282-3.

CISPLATIN [CDDP] 50 mg/m2 IV/30 min d1 q 21d

173

BOMP

Cervical Cancer

REF: Vogl SE, et al: CANCER TREAT REP. 1980; 64:1005-1007.

VINCRISTINE 1 mg/m2 (max 2) IV D1,8,22,29

BLEOMYCIN 10 units  (10,000 iu) IM weekly

CISPLATIN 50 mg/m2 IV/1h D1,22

MITOMYCIN-C 10 mg/m2 IVB D1 q 42d

172

BIP

Cervical Cancer

REFER: Buxton EJ: ACTA ONCOL 1988; 27:545-549.

BLEOMYCIN 30 units (30,000 iu) CIV over 24 hrs D1

IFOSFAMIDE 5 g/m2 CIV over 24 hrs D2

CISPLATIN 50 mg/m2 IV D2

MESNA [MESNA] 8 g/m2 CIV over 36 hrs...D2 q21

171

Fludarabine iv

CLL/ Low grade NHL

Ref: Skeel RT; Handbook of cancer chemotherapy, 5th Ed Lippincott, Williams and Wilkins 1999; 107-8.

Fludarabine 25 mg/m2 d1-5 q28

124

FluCyclo

CLL - MRC Protocol: Trial CLL4

Ref: O'Brien et al J Clin Oncol 19. 5:1414-20;2001

Fludarabine 25mg/m2 IV d1-3                OR          24mg/m2 PO d1-5         q28

Cyclophosphamide 250 mg/m2 IV d1-3 OR               150 mg/m2 PO d1-5    q28

125

FU-LEVAM

Colorectal cancer

REF: Moertel CG, et al: NEJM 1990; 322:352-358.

LEVAMISOLE 50 mg tid PO D1-3 d15-17

FLUOROURACIL 450 mg/m2 per day D1-5

Then at D28 begin

FLUOROURACIL 450 mg/m2 IV weekly x 48 weeks

LEVAMISOLE 50 mg tid PO D1-3 fortnightly x 48 weeks

CYCLE: Total Therapy - 1 year.

167

 

 

FU/LV#1

Colorectal Cancer

REF: Petrelli N, et al: J CLIN ONCOL 1989; 7:1419-1426.

Folinic Acid 500 mg/m2 Weeks 1-6

FLUOROURACIL [5-FU] 600 mg/m2 IV weeks 1-6 at midpoint of Leucovorin infusion

168

FU/LV#2

Colorectal Cancer

Ref: Maroun JA et al. Am J Clin Oncol. 20(4):378-92, 1997.

FLUOROURACIL [5-FU] 370 mg/m2 IV D1-5

Folinic Acid [Leu] 200 mg/m2 IV D1-5 q28

 

169

FU/LV#3

Colorectal Cancer

Ref: Ardalan, et al: J CLIN ONCOL 1991; 9:625-630

FLUOROURACIL 2600 mg/m2 d1 24 hrs inf CIV

Folinic Acid 500 mg/m2 d1 24 hrs inf CIV q7

170

FU/LV#4

 

Colorectal Cancer

BCCA Protocol

FLUOROURACIL [5-FU] 425 mg/m2 IV D1-5

Folinic Acid [Leu] 20 mg/m2 IV D1-5 q28

 252
FOLFIRI

Colorectal Cancer

BCCA Protocol

Irenotecan 180 mg/m2 d1

FLUOROURACIL [5-FU] 400 + 2400 mg/m2 IV D1-2

Folinic Acid [Leu] 200 mg/m2 IV D1 q14

 253

FOLFOX

Colorectal Cancer

BCCA Protocol

Oxaliplatin 100 mg/m2 d1

FLUOROURACIL [5-FU] 400 + 2400 mg/m2 IV D1-2

Folinic Acid [Leu] 400 mg/m2 IV D1 q14

 		254

LIPOSOMAL DOXORUBICIN

Cutaneous: Kaposi's

REF: Northfeld DW et al, J Clin Onc (15) 653-9, 1997

LIPOSOMAL DOXORUBICIN 20 mg/m2 IV/ D1 q21d

233

VP-16

Cutaneous: Kaposi's

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 373.

ETOPOSIDE 150 mg/m2 IV/4-6hr D1-3 q28d

216

HDI

 Cutaneous: Melanoma  

Ref:  Kirkwood JM, Ibrahim JG, Sosman JA, et al.  J Clin Oncol 2001;19(9):2370-80

Interferon 2b  20 MU/m2 d1-5 IV q7 - 4 cycles        then 

Interferon 2b   10MU/m2 sc Mon/Wed/Fri   x 48w

 277

VDP

Cutaneous: Melanoma

REF: Nathanson L: Melanomas ... In: Skeel RT, ed. Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 256. 

VINBLASTINE 5 mg/m2 IV D1,2

DACARBAZINE 150 mg/m2 IV D1-10

CISPLATIN 75 mg/m2 IV D5 Q21/28D

220

Cisplatin+ Dacarbazine

Cutaneous: Melanoma

REF: Albino AP, et al. Chapter 41: Malignant Melanoma. In: DeVita V. T. HS, Rosenberg S.A., ed. Cancer: Principles & Practice of Oncology - 5th Edition. Philadelphia: Lippincott-Raven Publishers, 1997:1935 - 2011.

DACARBAZINE 850 mg/m2 IV D1 

CISPLATIN 100 mg/m2 IV D1 q21d

278

DBPT

Cutaneous: Melanoma

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 256.

DACARBAZINE 220 mg/m2 IV D1-3 q 21d

CISPLATIN 25 mg/m2 IV D1-3 q21d

CARMUSTINE 150 mg/m2 IV D1 q42d

TAMOXIFEN 10 mg PO bd

217

ABV

Cutaneous: Kaposi=s

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 373.

DOXORUBICIN 40 mg/m2 IV D1

BLEOMYCIN 15000 iu/m2 IV D1,15

VINBLASTINE 6 mg/m2 IV D1 q28d

215

BORTEZOMIB

(Velcade)

Haematology: Myeloma

REF: 

BORTEZOMIB 1.3 mg/m2 IV D1,4,8,11 Q 21 D

281

DTIC3

Cutaneous: Melanoma

REF: 

DACARBAZINE 1100 mg/m2 IV D1 Q 21 D

279

DTIC2

Cutaneous: Melanoma

REF: DeVita VT Jr, et al: Cancer Principles and Practice of Oncology 3rd Ed. J.B.Lippincott Co. 1989; 1637.

DACARBAZINE 850 mg/m2 IV D1 Q 21/28 D

219

DTIC1

Cutaneous: Melanoma

REF: DeVita VT Jr, et al: Cancer Principles and Practice of Oncology 3rd Ed. J.B.Lippincott Co. 1989; 1522.

DACARBAZINE 250 mg/m2 IV D1-5 q21d

218

PAC-2

Endometrial Cancer

REF: Turbow MM, et al: PROC ASCO 1982; 1:108.

CISPLATIN 60 mg/m2 D1

DOXORUBICIN 50 mg/m2 D1

CYCLOPHOSPHAMIDE 600 mg/m2D1 q21/28

166

MCA

Endometrial Cancer

REF: Horton J, et al: CANCER 1982; 49:2441-2445.

MEGESTROL 80 mg TID PO od

CYCLOPHOSPHAMIDE [CTX] 400 mg/m2 IVB...D1

DOXORUBICIN 40 mg/m2 IVB D1 q 28 days

 159

PFL

Head and Neck

REF: Dreyfuss AI, et al: ANN INTERN MED 1990; 112:167-172.

CISPLATIN 25 mg/m2 CIV D1-5

FLUOROURACIL 800 mg/m2 CIV D2-6

LEUCOVORIN 500 mg/m2 CIV D1-6 Q28D

211

MBC

Head and Neck

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 153.

METHOTREXATE 40 mg/m2 IM/IV D1,15

BLEOMYCIN 10000 iu IM/IV D1,8,15

CISPLATIN 50 mg/m2 IV D4 q21d

210

COB

Head and Neck

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 152. CISPLATIN mg/m2 IV...D1

VINCRISTINE 1 mg IV D2,5

BLEOMYCIN 30000 iu CIV D2-5 q21

209

CF

Head and Neck

REFER: Kish JA, et al: CANCER 1985; 56:2740-2744.

CISPLATIN 100 mg/m2 IV D1

FLUOROURACIL 1000 mg/m2 4 CIV D1-4 q21d

208

PABLOE

Hodgkin=s Dis - BNLI/UKLG/MRC protocol

Trial:

Doxorubicin 40 mg/m2 d1

Vincristine 1.4 mg/m2 D1,8

Bleomycin 10,000 iu/m2 d1,8

Prednisolone 40mg/m2 d1-10

Etoposide 200mg/m2 d1-3

118

VAPEC-B

Hodgkin=s Dis - BNLI/UKLG/MRC protocol

Trial: LY07

Prednisolone 50 mg od d1-28

Doxorubicin 35mg/m2 d1; Cyclophosphamide 350 mg/m2 d1

Vincristine 1.4 mg/m2 d8,22; 

bleomycin 10000 iu/m2 d8,22

Doxorubicin 35 mg/m2 d15; etoposde 100 mg/m2 d15-19

123

ABVD

Hodgkin=s Dis - BNLI/UKLG/MRC protocol

Trials: LYO

Doxorubicin 25 mg/m2 d1 & d15 

Bleomycin 10 mg/m2 (10,000 iu/m2) d1 & d15

Vinblastine 6 mg/m2 d1 & d 15 Dacarbazine 375 mg/m2 d1 & d15

101

ChlVPP

Hodgkin=s Dis - BNLI/UKLG/MRC protocol

Trial LY09

Chlorambucil 6 mg/m2 days 1-14

Procarbazine 100 mg/m2 (max 200) days 1-14

Prednisolone 40 mg/m2 days 1-14

Vinblastine 6 mg/m2 days 1&8

104

Stanford V

Hodgkin=s Dis - 

Mustine 6 mg/m2  w 1, 5, 9

Doxorubicin HCl  25mg/m2  w 1, 3, 5, 7, 9

Vinblastine 6 mg/m2    w 1, 3, 5, 7, 9

Etoposiide   60 mg/m2 d1,2 of w 3, 7, 11

Prednisolone 40 mg/m2 alt day 12 weeks

Vincristine 1.4 mg/m2 w 2, 4, 6, 8, 10, 12

Bleomycin   5000iu /m2 w 2, 4, 6, 8, 10, 12

 138
BEACOPP

(standard/baseline)

Hodgkin=s Disease - 

Cyclophosphamide 650 mg/m2  d1

Doxorubicin HCl  25mg/m2  d1

Etoposide   100 mg/m2 d1,2, 3

Bleomycin   10mg/m2 d8

Vincristine 1.4 mg/m2 (max 2) d8

Procrbazine 100 mg/m2   D1-7

Prednisolone 40 mg/m2 D1-14   q21

 283
BEACOPP

ESCALATED

Hodgkin=s Disease - 

Cyclophosphamide 1250 mg/m2  d1

Doxorubicin HCl  35mg/m2  d1

Etoposide   200 mg/m2 d1,2, 3

Bleomycin   10mg/m2 d8

Vincristine 1.4 mg/m2 (max 2) d8

Procrbazine 100 mg/m2   D1-7

Prednisolone 40 mg/m2 D1-14   q21

 

 284
ICE Non-Hodgkin's Lymphoma - CORAL TRIAL

Ifosfamide 5 g/sqm d1 24h infusion

Etoposide 100 mg/sqm d1, d2 d3

Carboplatin 5 AUC (max 800 mg) D2     q21

 282

Rituximab

(rituxan)

(mabthera)

(anti-cd20)

Non-Hodgkin=s Lymphoma -

Rituximab 375 mg/sqm IV

112

MVP

Lung: Non Small Cell

REF: Bonomi PD, et al: J CLIN ONCOL 1989; 7:1602-1613. 

MITOMYCIN C 10 mg/m2 IV D1

VINBLASTINE 6 mg/m2 IV D1

CISPLATIN 40 mg/m2 IV D1 q 21d

192

FED

Lung: Non Small Cell

REF: Sridhar KS, et al: SEMIN IN SURG ONCOL 1993; 9:114-119. 

CISPLATIN 100 mg/m2 IV/over 3-4 hrs D1

ETOPOSIDE 80 mg/m2 IV D2,3,4

FLUOROURACIL 960 mg/m2 CIV...D2,3,4 Q 21D

191

CDDP+VP16

Lung: Non Small Cell

REF: Longeval E, et al: CANCER 1982; 50:2751-2756.

CISPLATIN 60 mg/m2 IV D1

ETOPOSIDE 100 mg/m2 IV D4,6,8 (OR D3,5,7) q 21/28d

190

CBDCA+VP16

Lung: Non Small Cell

REF: Klastersky JP: J CLIN ONCOL 1990; 8:1556-1562.

CARBOPLATIN 325 mg/m2 IV D1

ETOPOSIDE 100 mg/m2 IV D1-3 q 28d

189

CBDCA+VP16

Brain: Ependymoma

CARBOPLATIN 300 mg/m2 IV D1

ETOPOSIDE 100 mg/m2 IV D1 q 28d

 259

Cisplatin + Pemetrexed

Lung: Mesothelioma

CISPLATIN  75 mg/m2 IV D1

PEMETREXED  500 mg/m2 IV D1 q21d

 266

CAP

Lung: Non Small Cell

REF: Eagan RT, et al: CANCER TREAT REP 1979; 63:1589-1591.

CYCLOPHOSPHAMIDE 400 mg/m2 IV D1

DOXORUBICIN 40 mg/m2 IV D1

CISPLATIN 60 mg/m2 IV D1 Q 28D

188

CAE

Lung: Small Cell

REF: Rudolph A, et al: PROC ASCO 1983; 2:192.

CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1

DOXORUBICIN 45 mg/m2 IV D1

ETOPOSIDE [VP-16] 50 mg/m2 IV D1-5 q21d

196

CAV

Lung: Small Cell

REF: Roth BJ, et al: J CLIN ONCOL 1992; 10:282-291.

CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1

DOXORUBICIN 40 mg/m2 IV D1

VINCRISTINE 1 mg/m2 (max 2 mg)IV D1 q 21d

197

VIP(ICE)-2

(VIPP)

Lung: Non Small Cell

REF: Perez EA, et al: Cancer Cbemotherapy and Pharmacology 34(4): 331-4, 1994

IFOSFAMIDE 1 - 1.2 g/m2 IV D1-3

MESNA 0.4 g/m2 PO/IV qid

CISPLATIN 100 mg/m2 IV D1,8

ETOPOSIDE 60 - 75 mg/m2 IV D1-3 q 28d

195

PVP-16

Lung: Non Small Cell

REF: Klastersky J: SEMIN IN ONCOL 1986; 13(Suppl 3):104-114.

CISPLATIN 60 - 120 mg/m2 IV D1

ETOPOSIDE 50 - 120 mg/m2 IV D1-3 q 21/28d

194

NVB-CDDP

Lung: Non Small Cell

REF: LeChevalier T, et al: J CLIN ONCOL 1994; 12:360-367.

Vinorelbine (Navelbine) 30mg/m2 IV D1,8,15,22,29,35

Cisplatin 120 mg/m2 D1,29 q 42d

193

NAVP

Lung: Non Small Cell

Vinorelbine (Navelbine) 30mg/m2 IV d1,8

Cisplatin 30 mg/m2 D1,8 q 21d

 265

VINORELBINE

Lung: Non Small Cell

REF: LeChevalier T, et al: J CLIN ONCOL 1994; 12:360-367.

Vinorelbine (Navelbine) 30mg/m2 IV weekly

147

PAVE

Lung: Small Cell

CISPLATIN 30 mg/m2 IV D1

DOXORUBICIN 40 mg/m2 IV D1

ETOPOSIDE 100 mg/m2 PO d3,5 

VINCRISTINE 1mg/m2 IV D1 q 21d

 267

CAVE

Lung: Small Cell

REF: DeVore RF, et al: Current Therapy in Hematology-Oncology. Brain MC,

Carbone PP,eds. 4th Ed. B.C.Decker 1992;274-278. 

CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1

DOXORUBICIN 50 mg/m2 IV D1

ETOPOSIDE 50 mg/m2 d1-5

VINCRISTINE 1.5 mg/m2 (max 2mg) D1 q 21d

198

VIP(ICE)-1

Lung: Small Cell

REF: Faylona E, et al: PROC ASCO 1992; 11:307.

IFOSFAMIDE 1.2 g/m2 IV D1-4 with MESNA

CISPLATIN 20 mg/m2 per day IV D1-4

ETOPOSIDE 37.5 mg/m2 PO D1-5 Q 28d

201

EP

Lung: Small Cell

REF: DeVore RF, et al: Current Therapy in Hematology-Oncology. Brain MC, Carbone PP,eds. 4th Ed. B.C.Decker 1992;274-278. CISPLATIN 25 mg/m2 IV D1-3

ETOPOSIDE 100 mg/m2 IV D1-3 Q21D

200

CEV

Lung: Small Cell

REF: Comis RL: SEMIN IN ONCOL 1986; 13(Suppl 3):40-44.

CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1

VINCRISTINE 1.4 mg/m2 IV D1 (max 2mg)

ETOPOSIDE 50 mg/m2 IV D1

ETOPOSIDE 100 mg/m2 PO D2-5 Q21D

199

CAMP

Lung: Non Small Cell

REF: Bitran JD, et al: CANCER TREAT REP 1976; 60:1225-1230. CYCLOPHOSPHAMIDE 300 mg/m2 IV D1,8

DOXORUBICIN 20 mg/m2 IV D1,8

METHOTREXATE 15 mg/m2 IV D1,8

PROCARBAZINE 100 mg/m2 per day PO D1-10 q 28 d

187

C-WEEKLY

Multiple Myeloma - MRC protocol

Trial MYELOMA VIII

Cyclophospamide 400 mg/m2 po weekly

Prednisolone 40 mg/m2 po alt day

103

VAD

Multiple Myeloma

Dexamethasone 40 mg/day d1-4

Vincristine 0.4mg/d 96 hr infusion

doxorubicin 9mg/m2 96 hr infusion

122

ABCM

Multiple Myeloma - MRC protocol

Trials: MYELOMA VII & VIII

Adriamycin 30mg/m2 and BCNU 30mg/m2 day 1

Melphalan 6 mg/m2 and cyclophosphamide 100mg/m2 days 22-26 q42

100

C-VAMP

Multiple Myeloma - MRC protocol

Trial: Myeloma VII

Doxorubicin 9 mg/m2/day 96hr inf d1-4

Vincristine 0.4 mg/day 96 hr inf d1-4

Methylprednisolone 1g/m2 d1-5

Cyclophosphamide 500 mg d1,8,15 q21

111

CIDEX

Multiple Myeloma Rel - Riverside protocol

CCNU 40mg d1;

Idarubicin 10 mg/m2 po d1-3

Dexamethasone 10 mg bd d1-4 q21

106

MACOP-B

NHL

REF: Connors JM, et al (eds). Update on Treatment for Diffuse Large Cell Lymphoma. Wiley & Sons 1986; 37-43.

METHOTREXATE 400 mg/m2 IV weeks 2,6,10

LEUCOVORIN 15 mg PO QID 6 DOSES, start 24hr after MTX

DOXORUBICIN 50 mg/m2 IV weeks 1,3,5,7,9,11

CYCLOPHOSPHAMIDE 350 mg/m2 IV weeks 1,3,5,7,9,11

VINCRISTINE 1.4 mg/m2 IV weeks 2,4,6,8,10,12

BLEOMYCIN [BLEO] 10OOO iu/m2 IV weeks 4,8,12

PREDNISONE [Pred] 75 mg per day PO Tapered over last 15 days

156
C-VAD

(CVAD)

MULTIPLE MYELOMA

REF:  MRC  MYELOMA IX TRIAL

Dexamethasone 40 mg/day d1-4 AND d12-15

Vincristine 0.4mg/d 96 hr infusion

doxorubicin 9mg/m2/d 96 hr infusion

cyclophosphamide mg PO/IV D1,8,15  q21

152

CVP-1

NHL

REF: Bagley CM, et al: ANN INTERN MED 1972; 76:227-234

CYCLOPHOSPHAMIDE 400 mg/m2 OD PO D1-5

VINCRISTINE 1.4 mg/m2 IV D1

PREDNISONE100 mg/m2 per day PO D1-5 Q21

153

MIV

NHL

REF: Herbrecht R, et al: PROC ASCO 1991; 10:278.

MITOXANTRONE 10 mg/m2 IV D1

IFOSFAMIDE 1500 mg/m2 per day IV D1-3 With MESNA

ETOPOSIDE 150 mg/m2 per day IV D1-3 q21

157

IV

IV for Brain Tumour

 

IFOSFAMIDE 5000 mg/m2 IV D1 With MESNA

ETOPOSIDE 100 mg/m2 per day IV D1,2 q21

 262

PMitCEBO

NHL High Grade - BNLI/UKLG/MRC protocol

Trial: Sixty Plus

prednisolone 50-25 mg/day d1-14

Mitizantrone 7 mg/m2 d1

Etoposide 150 mg/m2 d1

Cyclophosphamide 300 mg/m2 d1

Vincristine 1.4 mg/m2 d8

Bleomycin 10000 iu/m2 d8

121

MiniBEAM

NHL High Grade relapse

Carmustine 60 mg/m2 d1

Cytarabine 100 mg/m2 d2-5

Etoposide 75 mg/m2 d2-5

Melphalan 30 mg/m2 d6

149

m-BACOD

NHL

REF: Shipp MA, et al: ANN INTERN MED 1986; 104:757-765.

METHOTREXATE 200 mg/m2 IV D8,15

Folinic acid 10 mg/m2 PO D9,16 qid x doses

BLEOMYCIN 4000 iu/m2 IV D1

DOXORUBICIN 45 mg/m2 IV D1

CYCLOPHOSPHAMIDE 600 mg/m2 IV D1

VINCRISTINE 1 mg/m2 IV D1

DEXAMETHASONE 6 mg/m2 per day PO D1-5 q21

158

BEAM

NHL High Grade relapse

Carmustine 300 mg/m2 d1

Cytarabine 200 mg/m2 d2-5

Etoposide 200 mg/m2 d2-5

Melphalan 140 mg/m2 d6

150

ESAP

NHL High Grade relapse

REF: Velasquez W, et al: PROC ASCO 1989; 8:256 

METHYLPREDNISOLONE 500 mg per day IV D1-4

ETOPOSIDE 40 mg/m2 per day IV D1-4

CYTARABINE 2 g/m2 IV D5

CISPLATIN [CDDP] 25 mg/m2 per day x 4 CIV D1-4

155

DHAP

NHL High Grade relapse

REF: Velasquez WS, et al: BLOOD 1988; 71:117-122.

CISPLATIN 100 mg/m2 CIV over 24 hrs D1

CYTARABINE [ARA-C] 2 g/m2 IV bd D2

DEXAMETHASONE 40 mg per day PO or IV D1-4 q21 or q28

154

COP-X

NHL High Grade, relapse - Nexstar protocol

Cyclophosphamide 750 mg/m2 d1

Liposomal daunorubicin 100 mg/m2 d1

Vincristine 1.4 mg/m2 d1

Prednisolone 100 mg od d1-5 q21

110

ESHAP

NHL High Grade, Relapse

Ref: Aparicio J et al.  ESHAP is an active regimen for relapsing Hodgkin's disease. Annals of Oncology 10(5); 593-5,1999

Methlyprednisolone 250 mg d1-5

Cisplatinum 25mg/m2/day d1-4

Etoposide 40mg/m2/day d1-4

Cytarabine 2g/m2 d5

114

CHOP

NHL High Grade - BNLI/UKLG/MRC protocol

Trial: LY02; Sixty plus

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 343.

Cyclophosphamide 750 mg/m2 d1

Doxorubicin 50 mg/m2 d1

Vincristine 1.4 mg/m2 d1

Prednisolone 100 mg od d1-5 q21

105

CNOP

NHL HIGH GRADE

Variant of CHOP

Cyclophosphamide 750 mg/m2 d1

Mitozantrone 12 mg/m2 d1

Vincristine 1.4 mg/m2 d1

Prednisolone 100 mg od d1-5 q21

108

PACEBO

NHL High Grade - BNLI/UKLG/MRC protocol

Trial: Sixty Plus

Prednisolone 50-25 mg/day d1-14

Doxorubicin 35 mg/m2 d1

Etoposide 150 mg/m2 d1

Cyclophosphamide 300 mg/m2 d1

Vincristine 1.4 mg/m2 d8

Bleomycin 10000 iu/m2 d8

119

COP (CVP)

NHL HIGH GRADE

Variant of CHOP

Cyclophosphamide 750 mg/m2 d1

Vincristine 1.4 mg/m2 d1

Prednisolone 100 mg od d1-5 q21

109

FAD

NHL Low Grade - BNLI/UKLG/MRC protocol

Trial: ?

Fludarabine 25mg/m2/day d1-3

Doxorubicin 50 mg/m2 d1

Dexamethasone 20mg/day d1-5 q21

115

PROMACE-

 CYTABOM

NHL

REF: Fisher RI, et al: PROC ASCO 1984; 242. Abstract.

PREDNISONE 60 mg/m2 per day PO D1-14

DOXORUBICIN 25 mg/m2 IV D1

CYCLOPHOSPHAMIDE 650 mg/m2 IV D1

ETOPOSIDE 120 mg/m2 IV D1

CYTARABINE 300 mg/m2 IV D8

BLEOMYCIN 5000 iu/m2 IV D8

VINCRISTINE 1.4 mg/m2 IV D8

METHOTREXATE 120 mg/m2 IV D8

LEUCOVORIN 25 mg PO D9 qidx 4 doses q21

160

CHOP-BLEO

NHL High Grade - BNLI/UKLG/MRC protocol

REF: Rodriguez V, et al: BLOOD 1977; 49:325-333.

Cyclophosphamide 750 mg/m2 d1

Doxorubicin 50 mg/m2 d1

Vincristine 1.4 mg/m2 d1,5 (max 2 mg)

Prednisolone 100 mg od d1-5

Bleomycin 15,000 iu od d1-5 q14 or q21

151

FMD

NHL LOW Grade - BNLI/UKLG/MRC protocol

Fludarabine 25mg/m2/day d1-3

Mitoxantrone ?12 mg/m2 d1

Dexamethasone 20mg/day d1-5 q21

116

PACEBOM

NHL High Grade - BNLI/UKLG/MRC protocol

Trial:

Prednisolone 50-25 mg/day d1-14

Doxorubicin 35 mg/m2 d1

Etoposide 150 mg/m2 d1

Cyclophosphamide 300 mg/m2 d1

Vincristine 1.4 mg/m2 d8

Methotrexate 100 mg/m2 d8

Bleomycin 10000 iu/m2 d8

120

CIOP

NHL High Grade - BNLI/UKLG/MRC protocol

Variant of CHOP

Cyclophosphamide 750 mg/m2 d1

Idarubicin 10 mg/m2 d1

Vincristine 1.4 mg/m2 d1

Prednisolone 100 mg od d1-5 q21

107

FU-PB-MMC

Oesophageal Cancer

CYCLE: Given with radiation - See reference.

REF: Leichman L, et al: J CLIN ONCOL 1987; 5:365-370. 

CISPLATIN 100 mg/m2 IV at 1mg/min D1,29

FLUOROURACIL 1000 mg/m2 CIV... D1-4,29-32

MITOMYCIN-C 10 mg/m2 IV bolus D57

BLEOMYCIN 20,000 iu CIV D57-60, 78-81

165

 

CDDP-FU-XRT

Oesophageal Cancer

REF: Herskovic A et al NEJM 1992, 326; 1593-8.

FLUOROURACIL 1000 mg/m2 CIV d1-4

CISPLATIN 75 mg/m2 IV/1mg/min D1 q21/28

164

 

FU-XRT

Pancreas

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 181.

FLUOROURACIL 500 mg/m2 D1-3, 29-31, XRT

FLUOROURACIL 500 mg/m2 FROM D 71 WEEKLY

222

HDMTX

Sarcoma: Bony/Osteo

REF: Perry MC: The Chemotherapy Sourcebook. Williams & Wilkins 1992; 766.

METHOTREXATE 8-12 g/m2 (max 20g)

Monitor urine pH and MTX plasma concentrations carefully

Folinic Acid 15-25 mg PO/IV qid 10 doses starting 24hrs post MTX q14/28d

203

A-DIC

Sarcoma: Soft Tissue

REFER: Baker LH et al J Clin Oncol 1987; 5:851-861. 

DOXORUBICIN 60 mg/m2 IV D1

DACARBAZINE 250 mg/m2 IV 1h D1 q21d

204

AC

Sarcoma: Bony/Osteo

REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co. 1991; 279.

DOXORUBICIN 75 - 90 mg/m2 CIV/96h D1-4

CISPLATIN 120 mg/m2 IA or IV D6 Q 28D

202

CYVADIC

Sarcoma: Soft Tissue

REF: Yap B-S, et al: CA TREAT REP 1980; 64:93-98.

CYCLOPHOSPHAMIDE 400-500 mg/m2 IV D1

Vincristine 1.5 mg/m2 (Max 2mg) d1,5

DOXORUBICIN 45-60 mg/m2 IV D1

DACARBAZINE 200-250 mg/m2 IV 1h D1-5 q21d

206

CYADIC

Sarcoma: Soft Tissue

REFER: Baker LH, et al: J CLIN ONCOL 1987; 5:851-861.

CYCLOPHOSPHAMIDE 400-500 mg/m2 IV D1

DOXORUBICIN 45-60 mg/m2 IV D1

DACARBAZINE 200-250 mg/m2 IV 1h D1-5 q21d

205

MAID

Sarcoma: Soft Tissue

REF: Elias AD, et al: PROC ASCO 1987; 6:134.

MESNA 2500 mg/m2 CIV D1-4

DOXORUBICIN 20 mg/m2 CIV D1-3

IFOSFAMIDE 2500 mg/m2 IV D1-3

DACARBAZINE 300 mg/m2 CIV D1-3 q21d

207

EFP

Small Bowel/GASTRIC CANCER

REF: Ajani J, Sixth Int Conf on the Adj ther of Cancer, Proc & Abstracts 1990; 396-404

ETOPOSIDE 90 mg/m2 per day IV D1,3,5

CISPLATIN 20 mg/m2 IV D1-5

FLUOROURICIL 900 mg/m2 CIV over 2 hrs D1-5 Q24-28

162

EAP

Small Bowel/GASTRIC CANCER

REF: Preusser P, et al: J CLIN ONCOL 1989; 7:1310-1317. 

ETOPOSIDE 120 mg/m2 per day IV D4-6

DOXORUBICIN 20 mg/m2 IV D1,7

CISPLATIN 40 mg/m2 IV over 2 hrs D2,8 Q21-28

161

FAM

Small Bowel/GASTRIC CANCER

REF: MacDonald JS, et al: ANN INTERN MED 1980; 93:533-536.

FLUOROURACIL 600 mg/m2 D1,8,29,36

DOXORUBICIN 30 mg/m2 D1,29

MITOMYCIN-C 10 mg/m2 IV D1 Q56

163

PVB

Testicular Cancer

REF: Williams SD, et al: NEJM 1987; 316:1435-1440.

VINBLASTINE 0.15 mg/kg IV D1,2(reduce by 20% if prior XRT)

CISPLATIN 20 mg/m2 per day IV D1-5

BLEOMYCIN 30,000 iu IV D2,9,16 q 21d

 

175

VIP-1

Testicular Cancer

REF: Loehrer PJ, et al: ANN INTERN MED 1988; 109:540-546.

ETOPOSIDE 75 mg/m2 IV D1-5

IFOSFAMIDE 1.2 g/m2 x 5 CIV D1-5

CISPLATIN 20 mg/m2 IV D1-5

MESNA 400 mg/m2 IV D1 15 min. pre ifos

MESNA 1.2 g/m2 per day x 5 CIV D1-5 q21d

176

VIP-2

Testicular Cancer

REF: Loehrer PJ, et al: ANN INTERN MED 1988; 109:540-546.

VINBLASTINE 0.11 mg/kg d1,2

IFOSFAMIDE 1.2 g/m2 ?x 5 CIV D1-5

CISPLATIN 20 mg/m2 IV D1-5

MESNA 400 mg/m2 IV D1 15 min. pre ifos

MESNA 1.2 g/m2 per day x ?5 CIV D1-5 q21d

177

BEP

Testicular Cancer

Ovarian Cancer - Germ Cell

REF: Williams SD, et al: NEJM 1987; 316:1435-1440.

ETOPOSIDE 100 mg/m2 per day IVD1-5(reduce by 20% if prior XRT)

CISPLATIN 20 mg/m2 per day IV D1-5

BLEOMYCIN 30,000 iu IV D2,9,16 q 21d

174

 

 

 

top